Telix Pharmaceuticals Ltd share price logo

Telix Pharmaceuticals Ltd Share Price

NASDAQ: TLX

Mid Cap

$9.80

-0.43

(-4.20%)

as on

Telix Pharmaceuticals Ltd Stock Performance

as on November 13, 2025 at 2:29 am IST

  • Day's Low

    Day's High

    $9.73
    $9.95
    downward going graph

    0.71%

    Downside

    1.53%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $8.93
    $30.36
    downward going graph

    8.88%

    Downside

    209.80%

    Upside

    downward going graph

Telix Pharmaceuticals Ltd share price movements today

Previous Close
$10.23
Open
$9.93
Volume
418.1K
Day's Low - High
$9.73 - $9.95
52 Week Low - High
$8.93 - $30.36

Telix Pharmaceuticals Ltd Historical Returns

1 Month Return
+ 2.83 %
3 Month Return
-12.25 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Telix Pharmaceuticals Ltd Stock Fundamentals & Key Indicators

Check Telix Pharmaceuticals Ltd market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$3.4B

EPS (TTM)

0.015

Dividend Yield

0.00%

PE Ratio (TTM)

511.5

Industry PE ratio

0

PEG Ratio

0

Return On Equity TTM

3.14%

Telix Pharmaceuticals Ltd Stock Valuation

Track how Telix Pharmaceuticals Ltd P/E has moved over time to understand its valuation trends.

Telix Pharmaceuticals Ltd in the last 5 years

  • Overview

  • Trends

Lowest (75.57x)

September 30, 2025

Industry (0.00x)

November 13, 2025

Today (511.50x)

November 13, 2025

Highest (114.85x)

March 31, 2025

LowHigh

Today’s Price to Earnings Ratio: 511.50x

Telix Pharmaceuticals Ltd vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Telix Pharmaceuticals Ltd with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Telix Pharmaceuticals Ltd image
Telix Pharmaceuticals Ltd
NA$3.4BNA511.51.63%
Insmed Incorporated image
Insmed Incorporated
BUY$41.5B437.88%-16.34-264.83%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$59.7B234.1%1412.341.36%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$108.9B92.53%30.2131.35%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$70.9B20.35%16.1832.13%

Telix Pharmaceuticals Ltd Quarterly Profit & Loss

All numbers in Millions USD

Dec 2020
Jun 2021
Dec 2021
Jun 2022
Dec 2022
Jun 2023
Dec 2023
Jun 2024
Dec 2024
Jun 2025
Total Revenue
3
2
4
24
136
220
281
188
594
593
Gross Profit
-8
-11
-18
-15
44
90
223
123
385
288
Operating Income
-29
-31
-49
-63
-9
31
20
13
68
15
EBITDA
-26
-28
-47
-60
-7
34
22
40
76
8
Interest Expense
0
0
0
0
0
0
0
4
16
3
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-35
-37
-61
-70
-27
-12
15
9
46
-7
Income Tax Expense
-8
-4
-13
0
5
2
-4
-2
8
3
Net Income
-26
-32
-47
-70
-33
-14
19
11
38
-3
Net Profit Margin
-737.27%
-1117.32%
-1024.24%
-294.80%
-24.39%
-6.48%
6.93%
6.18%
6.43%
-0.59%

Telix Pharmaceuticals Ltd Annual Profit & Loss

All numbers in Millions USD

Dec 2015
Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
32
29
31
0
3
5
7
160
336
495
Gross Profit
7
8
0
0
-11
-16
-29
29
210
322
Operating Income
0
0
-6
-15
-40
-49
-81
-91
51
82
EBITDA
0
0
-6
-25
-36
-44
-70
-92
22
98
Interest Expense
0
0
0
0
2
1
0
0
13
21
Depreciation
-
-
-
-
-
4
5
5
6
-
Income Before Tax
0
0
-6
-15
-42
-60
-99
-98
3
56
Income Tax Expense
0
0
0
-1
-14
-15
-18
5
-2
6
Net Income
0
0
-6
-13
-27
-44
-80
-104
3
31
Net Profit Margin
-0.41%
-0.15%
-20.07%
-7087.06%
-799.63%
-861.06%
-1059.90%
-65.01%
1.04%
6.37%

Telix Pharmaceuticals Ltd Quarterly Cash Flow

All numbers in Millions USD

Jun 2021
Dec 2021
Jun 2022
Dec 2022
Jun 2023
Dec 2023
Jun 2024
Dec 2024
Jun 2025
Net Income
-32
-47
-70
-33
-14
19
11
-11
-3
Operating Cash Flow
-28
-30
-60
-3
13
10
34
3
26
Investing Cash Flow
0
-1
-11
-5
-2
-22
-45
-89
-393
Financing Cash Flow
0
2
171
3
4
5
3
635
-4
Change in Cash
-28
-27
100
-6
15
-8
-3
591
314

Telix Pharmaceuticals Ltd Annual Cash Flow

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
0
-6
-13
-27
-44
-80
-104
5
49
Operating Cash Flow
-1
-6
-20
-23
1
-59
-63
23
43
Investing Cash Flow
-1
0
-2
0
-1
-2
-16
-25
-135
Financing Cash Flow
3
54
0
42
34
2
174
10
638
Change in Cash
0
54
-22
18
33
-55
94
6
587

Insights on Telix Pharmaceuticals Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 6 months, TLX stock has moved down by -41.3%

About Telix Pharmaceuticals Ltd

Telix Pharmaceuticals Limited is an Australia-based is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. It operates under four business units: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech), and Telix Manufacturing Solutions (TMS). Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx.
OrganisationTelix Pharmaceuticals Ltd
Headquarters55 Flemington Road, North Melbourne, VIC, Australia, 3051
CEODr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA
E-voting on sharesClick here to vote

Key Management of Telix Pharmaceuticals Ltd

Name

Title

Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA

Co-Founder, MD, Group CEO & Executive Director

Mr. Darren Smith B.Bus., FCPA, M.B.A.

Group Chief Financial Officer

Mr. Darren Patti Pharm.D.

Group Chief Operating Officer

Dr. Andreas Kluge M.D., Ph.D.

Chief Medical Advisor

Dr. David N. Cade M.B.A., M.D., MBBS

Group Chief Medical Officer

Mr. Richard Valeix M.B.A.

Chief Executive Officer of Telix Therapeutics

FAQs

What is Telix Pharmaceuticals Ltd share price today?

Telix Pharmaceuticals Ltd share price today is $9.8 as on at the close of the market. Telix Pharmaceuticals Ltd share today touched a day high of $9.95 and a low of $9.73.

What is the 52 week high and 52 week low for Telix Pharmaceuticals Ltd share?

Telix Pharmaceuticals Ltd share touched a 52 week high of $30.36 on and a 52 week low of $8.93 on . Telix Pharmaceuticals Ltd stock price today i.e. is closed at $9.8,which is 67.72% down from its 52 week high and 9.74% up from its 52 week low.

What is Telix Pharmaceuticals Ltd's market capitalisation today?

Telix Pharmaceuticals Ltd market capitalisation is $0.00T as on .

How to invest in Telix Pharmaceuticals Ltd Stock (TLX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Telix Pharmaceuticals Ltd on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Telix Pharmaceuticals Ltd Shares that will get you 0.1531 shares as per Telix Pharmaceuticals Ltd share price of $9.8 per share as on November 13, 2025 at 2:29 am IST.

What is the minimum amount required to buy Telix Pharmaceuticals Ltd Stock (TLX) from India?

Indian investors can start investing in Telix Pharmaceuticals Ltd (TLX) shares with as little as ₹88.618 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹886.18 in Telix Pharmaceuticals Ltd stock (as per the Rupee-Dollar exchange rate as on ). Based on Telix Pharmaceuticals Ltd share’s latest price of $9.8 as on November 13, 2025 at 2:29 am IST, you will get 1.0204 shares of Telix Pharmaceuticals Ltd. Learn more about fractional shares .